Adherence Intervention in Patients With Metastatic Breast Cancer
NCT ID: NCT06121453
Last Updated: 2025-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
NA
35 participants
INTERVENTIONAL
2024-04-12
2026-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reducing Underuse of Early-Stage Breast Cancer Treatment in Minority Communities
NCT00145197
Mobile Health (mHealth) Black Women With Breast Cancer
NCT02463474
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
NCT07076147
Patient Centered Randomized Controlled Trial
NCT00233077
Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient
NCT03007641
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single Arm: Adherence Intervention
Multicomponent Adherence Intervention
Multicomponent Adherence Intervention
multi-part intervention to reduce barriers to medication use
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multicomponent Adherence Intervention
multi-part intervention to reduce barriers to medication use
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with stage IV/metastatic breast cancer prescribed endocrine therapy and a CDK4/6i
* Prescribed at least 1 antihypertensive or statin medication for CVD prevention or treatment
* Self-report of at least some nonadherence ET/CDK4/6i or CVD medication on nonadherence screener or verbally to a treating clinician, or nonadherent to ET, CDK4/6i, and/or CVD medication on pharmacy fill data in the EHR (proportion of days covered over prior 180 days \<80%).
Exclusion Criteria
* Not cognitively able to complete study requirements
* Inability to provide informed consent for any other reason (e.g, severe psychiatric illness, active substance use)
* Unavailable for 28 weeks of follow-up
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Minority Health and Health Disparities (NIMHD)
NIH
Columbia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Claire Sathe, MD
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Columbia University Medical Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AAAU9129
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.